Seasonal influenza, respiratory syncytial virus (RSV), and COVID-19 are actively circulating throughout the United States.

Dimerix has achieved a key milestone in its ACTION3 phase III trial of lead asset DMX-200 into focal segmental ...

The following is a summary of “Monocytic reactive oxygen species-induced T cell apoptosis impairs cellular immune response to ...

Peptides have emerged as a focal point in molecular and biological research, providing a promising avenue for understanding ...

placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Planned blinded interim data ...

This ACTION3 phase III trial is a randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II ...

Hypertension, also known as high blood pressure, is the most common cardiovascular risk factor. It describes a condition where the force of blood pushing against the walls of blood vessels called ...

Abstract We investigated the effects of angiotensin II (Ang II) type 1 receptor blockade with losartan on the renin-angiotensin-aldosterone system in hypertensive patients (supine diastolic blood ...

The probability of event-free survival in patients receiving valsartan 160 mg b.i.d. vs. placebo in addition to optimal medical therapy in patients with systolic heart failure (Kaplan-Meier ...

This phase III trial is a randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor ...